Avita Medical (NASDAQ:RCEL) Director Joseph Fralin Woody Acquires 10,000 Shares

Posted by Geri Gentry on Jun 5th, 2026

Avita Medical Inc. (NASDAQ:RCEL – Get Free Report) Director Joseph Fralin Woody acquired 10,000 shares of Avita Medical stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $4.09 per share, with a total value of $40,900.00. Following the completion of the transaction, the director owned 92,761 shares of the company’s stock, valued at approximately $379,392.49. This trade represents a 12.08% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Joseph Fralin Woody also recently made the following trade(s):

On Monday, June 1st, Joseph Fralin Woody acquired 10,000 shares of Avita Medical stock. The shares were bought at an average cost of $4.30 per share, with a total value of $43,000.00.

Avita Medical Price Performance

RCEL stock traded down $0.18 during midday trading on Friday, reaching $4.18. 297,655 shares of the company were exchanged, compared to its average volume of 237,243. The business has a 50-day moving average price of $4.35 and a two-hundred day moving average price of $4.12. Avita Medical Inc. has a one year low of $3.22 and a one year high of $7.12. The firm has a market capitalization of $128.65 million, a price-to-earnings ratio of -2.66 and a beta of 1.87.

Avita Medical (NASDAQ:RCEL – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). The company had revenue of $19.25 million for the quarter, compared to the consensus estimate of $18.30 million. As a group, analysts anticipate that Avita Medical Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RCEL. Rhumbline Advisers boosted its holdings in shares of Avita Medical by 8.8% during the 2nd quarter. Rhumbline Advisers now owns 42,168 shares of the company’s stock worth $223,000 after buying an additional 3,393 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Avita Medical by 122.2% in the 4th quarter. Russell Investments Group Ltd. now owns 8,047 shares of the company’s stock worth $28,000 after purchasing an additional 4,425 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Avita Medical by 1,351.5% in the 4th quarter. Deutsche Bank AG now owns 7,896 shares of the company’s stock worth $27,000 after purchasing an additional 7,352 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Avita Medical by 98.5% in the 4th quarter. Wells Fargo & Company MN now owns 18,832 shares of the company’s stock worth $65,000 after purchasing an additional 9,345 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Avita Medical by 20.4% in the 1st quarter. Jane Street Group LLC now owns 63,744 shares of the company’s stock worth $519,000 after purchasing an additional 10,789 shares in the last quarter. Institutional investors and hedge funds own 27.66% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on RCEL. Lake Street Capital raised shares of Avita Medical from a “hold” rating to a “buy” rating and boosted their target price for the company from $3.50 to $6.00 in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Avita Medical in a research report on Friday, March 27th. Wall Street Zen cut shares of Avita Medical from a “hold” rating to a “sell” rating in a research report on Sunday, May 24th. Northland Securities began coverage on shares of Avita Medical in a research report on Thursday, March 5th. They issued an “outperform” rating and a $10.00 target price for the company. Finally, D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Avita Medical in a research report on Wednesday, April 8th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $7.25.

Get Our Latest Research Report on Avita Medical

About Avita Medical

(Get Free Report)

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.